News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NDA For Eagle Pharmaceuticals (EGRX)' Orphan Drug Ryanodex® For The Treatment Of Malignant Hyperthermia Accepted By FDA, Priority Review Granted


3/20/2014 10:00:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. ("EAGLE") (NASDAQ:EGRX) announced today that the United States Food and Drug Administration has accepted the company’s New Drug Application for Ryanodex® (dantrolene) and granted a priority review classification. The PDUFA date is July 22, 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES